REGEN-Cov antibody combination to prevent COVID-19 infection in kidney transplant recipient without detectable antibody response to optimal vaccine scheme-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

REGEN-Cov antibody combination to prevent COVID-19 infection in kidney transplant recipient without detectable antibody response to optimal vaccine scheme

Published:2022-03 Issue:3 Volume:101 Page:645-646
ISSN:0085-2538
Container-title:Kidney International
language:en
Short-container-title:Kidney International

Author:

Ducloux Didier^ORCID,Courivaud Cécile

Publisher

Elsevier BV

Subject

Nephrology

Reference5 articles.

1. Factors associated with humoral response after BNT162b2 mRNA COVID-19 vaccination in kidney transplant patients;Ducloux;Clin Kidney J,2021

2. Humoral response after SARS-CoV-2 mRNA vaccination in a cohort of hemodialysis patients and kidney transplant recipients;Danthu;J Am Soc Nephrol,2021

3. Is COVID-19 infection more severe in kidney transplant recipients?;Caillard;Am J Transplant,2021

4. Covid-19 Phase 3 Prevention Trial Team. Subcutaneous REGEN-COV antibody combination to prevent Covid-19;O'Brien;N Engl J Med,2021

5. The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies;Copin;Cell,2021

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and efficacy of tixagevimab/cilgavimab for pre-exposure prophylaxis in kidney transplant recipients: a multicenter retrospective cohort study;Journal of Nephrology;2024-05-23

2. Prevention and treatment strategies for kidney transplant recipients in the context of long-term existence of COVID-19;Frontiers in Medicine;2024-04-03

3. Challenges Faced by Solid Organ Transplant Recipients During the COVID-19 Pandemic in France: Historical Insights and Key Takeaways;Transplantation;2024-03-23

4. SARS-CoV-2 Omicron BA.1/BA.2 Neutralization up to 8 Weeks After PrEP With Sotrovimab or Cilgavimab/Tixagevimab;Transplant International;2022-12-12

5. COVID-19 Breakthrough Infections in Vaccinated Kidney Transplant Recipients;Vaccines;2022-11-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3